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Abstract
Intermolecular contacts between integrin LFA-1 (aLb2) and ICAM-1 derive solely from the integrin aL I domain and the first
domain (D1) of ICAM-1. This study presents a crystal structure of the engineered complex of the aL I domain and ICAM-1 D1.
Previously, we engineered the I domain for high affinity by point mutations that were identified by a directed evolution
approach. In order to examine aL I domain allostery between the C-terminal a7-helix (allosteric site) and the metal-ion
dependent adhesion site (active site), we have chosen a high affinity variant without mutations directly influencing either
the position of the a7-helix or the active sites. In our crystal, the aL I domain was found to have a high affinity conformation
to D1 with its a7-helix displaced downward away from the binding interface, recapitulating a current understanding of the
allostery in the I domain and its linkage to neighboring domains of integrins in signaling. To enable soluble D1 of ICAM-1 to
fold on its own, we also engineered D1 to be functional by mutations, which were found to be those that would convert
hydrogen bond networks in the solvent-excluded core into vdW contacts. The backbone structure of the b-sandwich fold
and the epitope for I domain binding of the engineered D1 were essentially identical to those of wild-type D1. Most
deviations in engineered D1 were found in the loops at the N-terminal region that interacts with human rhinovirus (HRV).
Structural deviation found in engineered D1 was overall in agreement with the function of engineered D1 observed
previously, i.e., full capacity binding to aL I domain but reduced interaction with HRV.
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Introduction
Integrins are noncovalently associated ab heterodimeric cell
surface receptors that mediate cell-cell and cell-extracellular
matrix adhesions, signaling bidirectionally across the plasma
membrane. Integrins play important roles in development,
immune cell trafficking and responses, and homeostasis [1,2,3].
One of the major leukocyte integrins is the lymphocyte function-
associated antigen (LFA)-1, which provides the interactions
necessary for immunological synapse formation and adhesion to
endothelial cells [4]. Ligands of LFA-1 include intercellular
adhesion molecules (ICAMs; ICAM-1, -2, -3, -4, and -5) [5] and
junctional adhesion molecule (JAM)-1 [6], both of which are the
members of the immunoglobulin superfamily (IgSF) receptors. As
one of the most biologically important ligands for LFA-1, ICAM-1
is expressed at a low constitutive level in diverse types of cells and
tissues, while its expression is greatly upregulated in response to
inflammation [7] and in some tumors and their stroma
[8,9,10,11,12,13,14]. The interaction of LFA-1 and ICAM-1 is
contained within the single domains called the a I domain in LFA-
1 and the first N-terminal domain (D1) of ICAM-1. ICAM-1 is
also subverted as a receptor for human rhinovirus (HRV): the
epitopes for both HRV and LFA-1 are within D1, yet they are
distinct [15].
Previous structural studies have indicated that the I domains of
both a and b chains exhibit low to high affinities to their ligands
[16,17]. Distinct conformational changes have been observed
between the top of the I domains known as the metal ion-
dependent adhesion site (MIDAS) and the C-terminal a-helix
(designated as a7-helix), a molecular coupling characterized as
‘allostery’. The displacement of the a7-helix (allosteric site)
‘downward’ (with respect to the top defined as the binding
interface of the I domain with ligands) has been hypothesized to
cause a change in the coordination to the metal ion of the residues
in the MIDAS (active site), leading to a higher affinity
conformation [18]. For integrins containing I domains in the a
subunits, the downward ‘pull’ of the a7-helix is coupled to global
conformational rearrangements of integrins, and more specifically,
to the opening of the integrin headpiece and the separation of a
and b subunits at the plasma membrane [19]. Structural change in
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plasma membrane, termed ‘‘outside-in’’ and ‘‘inside-out’’ signaling
[1]. The LFA-1 a I domain is functionally expressed in isolation,
but is dominantly in a low affinity conformation to physiologic
ligands. A structural linkage between the MIDAS and the a7-
helix, i.e. allostery in a I domains, has been demonstrated by
rationally designed mutational studies [17,20] and by a molecular
simulation study [21]. However, no previous crystal structures of a
I domains in complex with physiological ligands were obtained
with the native sequence in the a7-helix and the residues in
contact with the a7-helix. Compared to the rationally designed
activating mutations in the LFA-1 a I domain, we previously
reported an application of directed evolution to select active I
domains from a library through a selective pressure for binding to
ICAM-1 [22]. Several point mutations away from the allosteric
site within and in the vicinity of the a7-helix were identified, which
induced higher affinity to ICAM-1.
The ectodomain of ICAM-1 contains five Ig-like domains with
the first domain D1 solely responsible for interactions with LFA-1
and HRV. The binding sites in D1 for LFA-1 and HRV, however,
are distinct. The loops at the N-terminal face of D1 interact with
HRV by docking into a region known as the canyon [15,23],
whereas the residues within the b-strands make contact with the I
domain [17]. Despite the modular nature of many IgSF domains,
D1 does not fold on its own unless it is expressed with the second
domain D2 [15,24]. In an attempt to achieve a physiologic fold,
we have previously engineered D1 by directed evolution [25]. A
set of extensive and concurrent mutations in D1 were necessary to
express D1 on its own that is competent for binding to the LFA-1 I
domain and conformation-specific antibodies. We have previously
noted that D1 contains a hydrogen bond network in the core of
the domain and that the mutations selected for the native
conformation were mainly those converting hydrogen bond
interactions to hydrophobic, van der Waals (vdW) contacts.
Engineered D1 retained an interaction with the I domain,
comparable to the wild-type ICAM-1. However, full-length
ICAM-1 containing the mutations found in D1 exhibited lower
binding to HRV [25], implying that conversion of the hydrogen
bond network into vdW contacts may be responsible for reduced
interaction with the virus.
Here we report the crystal structure of the complex between the
engineered LFA-1 I domain and ICAM-1 D1. Distinct from the
previous studies [17,20,26], we used a high-affinity I domain
mutant with one substitution (F265S), while preserving the native
sequence for the residues that are within or in direct contact with
the a7-helix. Despite the relatively low resolution of the structure,
we were able to establish that the a7-helix of the I domain in
complex with ICAM-1 D1 was indeed displaced downward,
comparable to the open conformations previously observed in aM
and a2 I domains [27,28]. This recapitulates structural, allosteric
linkage between the MIDAS and the position of a7-helix.
Furthermore, the backbone structure of bacterially-expressed
ICAM-1 D1, which contains many mutations and is devoid of
molecular contacts with D2, was found to be closely superimpos-
able to the previously solved D1 structures within D1D2 fragments
expressed in mammalian systems.
Results
Structural Evidence for Allosteric Linkage between the
MIDAS and the Position of the a7-helix in the LFA-1 I
Domain
Molecular contacts with the ligands by integrins, which contain
the inserted or I domain in the a subunit, are contained solely
within the I domain. In an inside-out signaling, a cascade of intra-
and inter-domain conformational change occurs that propagates
intracellular signals to ultimately the activation of the a I domain:
a transition pathway follows the separation of a and b subunits at
the plasma membrane, swing-out motion of the hybrid domain,
activation of the I domain present in b subunit, and a final step of
the activation of I domain in the a subunit (Fig. 1A&B). In the
process of integrins engaging with their ligands, the downward
‘pull’ of the a7-helix located at the C-terminal end of the a I
domain switches the MIDAS from low to high affinity conforma-
tion. To obtain a complex structure of the I domain with the
ligands, aL I domain, which maintains a modular function in
isolation, has been engineered to high affinity by mutations, such
as a pair of cysteines (K287C/K294C) to lock the a7-helix in an
active conformation [17] or double mutations (F265S/F292G)
that were identified by a directed evolution approach [22]. In an
attempt to examine a physiologically attainable, high affinity
conformation of the a7-helix with the least amount of perturba-
tion, we chose the I domain with single substitution of Ser for Phe-
265, a position located within b5-a6 and is not in direct contact
with the residues in the a7-helix (Fig. 1C & Fig. 2). ICAM-1 D1
was previously engineered with seven mutations to achieve a
native fold on its own with the affinity to the I domain comparable
to that of the wild-type ICAM-1 D1D2 or D1-D5 [25]. The
complex structure shows docking of Glu-34 in ICAM-1 D1 to a
divalent metal ion (Mg
2+) of the MIDAS (Fig. 1C), identical to the
previous integrin-ligand complex structures [17,20,26,28]. Even
with the native sequence in the a7-helix and its preceding b6-a7
loop, the I domain was found in an open conformation with the
a7-helix positioned downward, away from the closed state found
in the wild-type (Fig. 1D&E). The backbone structure of the b6-
strand and the a7-helix shown with electron density was found in
the open state (Fig. 1D). The b6-strand and the a7-helix contain
three hydrophobic residues, Leu-289, Phe-292, and Leu-295,
which in concert determine the position of the a7-helix (open,
intermediate, and closed) and the corresponding low or high
affinity conformations of the MIDAS. Compared to the previous
structures of the aM and a2 I domains, the aL I domain in our
crystal structure exhibited a comparable extent of downward
displacement of the a7-helix (Fig. 1E).
In contrast to one or two ICAM-1 D1D2 molecules or
complexes per asymmetric unit (1MQ8, 1IAM, and 1IC1),
notably a total of 14 complexes per asymmetric unit with a large
unit cell dimension were found in our structure (Fig. 1F & Table 1).
This may be partly ascribed to the interaction between two D1
fragments at the C-terminal face (indicated with dotted circles in
Fig. 1F), which is naturally buried if D2 is present. However, the
structural deviation (root-mean-square deviation (RMSD)) of all
14 complexes from each other was less than 0.41 A ˚. The largest
deviations among the 14 complexes were found at the a7-helix of I
domain (RMSD=0.56 A ˚) and the loops connecting b-strands at
the N-terminal face of ICAM-1 D1 (RMSD=0.67 A ˚). The loops
at the N-terminal face of ICAM-1 are also the regions that varied
most among all previous crystal structures either in complex with
aL I domain or on its own (Fig. 1G).
Comparison with the Previous Structures of High-affinity
LFA-1 I Domain Variants in Complex with Physiologic
Ligands
The LFA-1 I domain has previously been cocrystallized with
ICAM-1 D1D2 [17], ICAM-3 D1 [20], and ICAM-5 D1D2 [26]
(Fig. 2). All of the I domain structures were closely superimposable
at the structurally invariant central b-sheet, with most deviations
found in the b5-a6 loop, b6-a7 loop, and a7-helix. The affinity of
Complex Structure of ICAM-1 D1 and LFA-1 I Domain
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ICAM-1, and the I domain with two point mutations of F265S/
F292G were necessary to form a stable complex for crystallization
(Fig. 2A) [26]. However, the a7-helix was found flipped upward
pivoting on Gly-292 in the b6-a7 loop and the vacated space was
then occupied by the a7-helix belonging to a neighboring I
domain within the crystal unit (Fig. 2A). This unnatural
conformation of the a7-helix would be attributed to a greater
flexibility in dihedral angles along the peptide backbone around
Gly substituted for Phe-292. However, the backbone structure
excluding the a7-helix (Asn-129 to Leu-289) of the F265S/F292G
mutant was closely superimposable (0.6 A ˚ RMSD) to the I domain
containing only F265S. In complexes with ICAM-1 D1D2 and
ICAM-3 D1, the I domains contained substitutions of two
cysteines, which were introduced to lock the a7-helix in the
intermediate (L161C/F299C) and the open (K287C/K294C)
positions (Fig. 2B&C) [17,20]. Compared to these disulfide bridge
mutants, the b5-a6 loop (Gly-262 - Glu-272) of our structure was
more closely superimposable to that in the high affinity mutant
(RMSD=1.8 A ˚) than that in the intermediate affinity mutant
(RMSD=3.1 A ˚) (Figures 2B and 2C). At the same time, the b6-a7
loop (Lys-276 - Val-286) of our structure was also more closely
Figure 1. Complex structure of engineered aL I domain and ICAM-1 D1. (A&B) Schematic drawings of the integrin headpiece, denoting intra-
and inter-domain rearrangements during the engagement of LFA-1 with ICAM-1. A structural transition from low (A) to high affinity conformation (B)
involves downward displacement of the a7-helix, shape change in metal-ion coordination sites, and swing-out movement of the hybrid domain.
SyMBS=synergistic metal binding site; MIDAS=metal-ion dependent adhesion site; ADMIDAS=adjacent to MIDAS. (C) Ribbon diagram of the
engineered aL I domain (pale yellow), containing a substitution of F265S, in complex with the engineered domain 1 (D1) of ICAM-1 (light purple). The
residues coordinating to the metal ion in the MIDAS, Ser-139, Ser-141, and Thr-206 in I domain and Glu-34 in ICAM-1 D1 are shown in stick models.
The Mg
2+ ion is shown as a pink sphere. (D) The electron density map, drawn together with cartoon or stick models, shows an open conformation of
the b6-strand and the a7-helix. The three hydrophobic residues (Leu-289, Phe-292, and Leu-295; cyan) are shown in stick models. (E) In comparison to
the previous open structures of the I domains of different a subunits, aM (1IDO; blue) [27] and a2 (1DZI; green) [28], the a7-helix in our structure
(3TCX; magenta) shows a comparable extent of downward displacement, away from the closed structure seen in the wild-type aL I domain (3F74;
yellow) [44]. (F) Ribbon diagrams of 14 complexes found in an asymmetric unit. I domains are drawn in grey, and 14 molecules of D1 are drawn in
different colors for clarity. Dotted circles in cyan color indicate the interface between two C-terminal ends of D1. (G) Superimposed 14 complexes are
shown as Ca-traces.
doi:10.1371/journal.pone.0044124.g001
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K294C) than to the intermediate affinity mutant (RMSD=2.7 A ˚
to L161C/F299C), implying that our structure adopted a high
affinity conformation in the absence of mutations directly altering
the position of the a7-helix.
Structure of the Engineered ICAM-1 D1 Single Domain in
Comparison with the Previous Wild-type Structures
Unlike the retention of a modular function of the I domain on
its own, functional expression of D1 by itself was achieved only
after the introduction of seven mutations (T2V/A, I10T, T23A,
P38V/A, P63V, S67A, T78A) into Gln1-Thr85 sequence,
identified by the combination of directed evolution and rational
design approaches [25]. Except for the mutations I10T and P38V,
the remaining five mutations were located in solvent-excluded
regions (Fig. 3A–C), converting polar residues into hydrophobic
ones. Substitutions of T2V, T23A, and S67A would disrupt the
hydrogen bond interactions near the N-terminal face of the
domain and create hydrophobic, vdW contacts (Fig. 3B). Substi-
tutions of P63V and T78A also create new vdW contacts in the
protein core (Fig. 3C). For future structural studies with HRV,
Gln-1 was mutated into Met to avoid an extra residue being
appended to the N-terminal [29], which has been shown to grossly
compromise ICAM-1 binding to HRV [30].
The backbone structure of the mutant D1 along the b-strands
was closely superimposable to D1 structures in wild-type D1D2
fragments (0.5 A ˚ RMSD to 1IAM & 0.7 A ˚ RMSD to 1IC1) or in
D1D2 in complex with the LFA-1 I domain (0.6 A ˚ RMSD to
1MQ8) (Fig. 3D). The largest deviations of the mutant D1 from
the wild-type structures as well as the largest among the wild-type
Figure 2. Comparison with the previous complex structures of the aL I domain with ligands. (A–C) Superimposed to the current aL I
domain and ICAM-1 D1 structure (3TCX; magenta) are the previously solved complex structures of (A) high affinity (HA) aL I domain containingF265S/
F292G with ICAM-5 D1D2 (3BN3; yellow) [26], (B) intermediate affinity (IA) aL I domain containing L161C/F299C with ICAM-1 D1D2 (1MQ8; blue) [17],
and (C) high affinity (HA) aL I domain containing K287C/K294C with ICAM-3 D1 (1T0P; green) [20]. The acidic residue of the ICAMs (Glu-34 in ICAM-1
and Glu-37 in ICAM-3 and ICAM-5) docking into the I domains and the Mg
2+ ions are shown as stick and spheres, respectively. The b5-a6 and b6-a7
loops are circled with dotted lines.
doi:10.1371/journal.pone.0044124.g002
Table 1. Data Collection and Refinement Statistics.
Space group P212121
a( A ˚) 104.0
b( A ˚) 166.3
c( A ˚) 299.4
Molecules/asymmetric unit 14
Resolution (A ˚) 50-3.6 (3.66-3.6)
Unique reflections 58846 (2499)
Completeness (%) 96.2 (83.9)
Rsym (%) 12.4 (48.6)
,I/s(I). 14.6 (1.7)
Redundancy 5.5 (2.2)
Rwork/Rfree (%) 21.8/23.4
Ramachandran Plot (favored/allowed/outlier %) 89.74/8.05/2.22
Average B factor (A ˚ 2)
ICAM-1 D1 120.3
LFA-1 I domain 185.6
ICAM-1 D1+ LFA-1 I domain 165.7
RMSD from ideal values
Bond lengths (A ˚) 0.013
Bond angles (u) 1.418
Number in parentheses are for the highest resolution shell.
doi:10.1371/journal.pone.0044124.t001
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together create the contours of the N-terminal face (Fig. 3D &
Fig. 4). These loops are in close contact with HRV as seen in the
model structure generated from cryo-EM electron density (Fig. 3F)
[31,32,33]. From our previous observation that the mutations into
a triad forming a hydrogen bond network near the N-terminal face
were responsible for the reduced binding to HRV [25], it can be
speculated that our vdW forming mutations influenced the flexible
nature of the N-terminal loops [24], which may be necessary for
fitting into the viral capsid. We noted that Ca-Ca distances among
Thr-2, Thr-23, and Ser-67 in the wild-type structures were slightly
reduced in the D1 mutant with T2V, T23A, and S67A
substitutions (Fig. 3E). Substitutions with smaller side chains (i.e.,
T23A and S67A) in turn would have affected the interaction with
the neighboring residues, thus placing the B–C loop closer toward
the protein core (Fig. 3E). In contrast, the interface with the I
domain is contained within the region where the backbone of
engineered D1 was closely superimposable to that of the wild-type,
unaffected by the deviation seen in the loops (Fig. 3G & Fig. 4).
Discussion
Here we report the crystal structure of the complex of LFA-1 a I
domain and ICAM-1 D1, which have been engineered for high
affinity and native fold, respectively. A point mutation in the LFA-
1 I domain (F265S), which resulted in an increase in affinity to
ICAM-1 by ,10,000 fold over the wild-type I domain [22], was
sufficient to trigger allosteric shifting of the MIDAS into a high
Figure 3. Structural deviation in engineered ICAM-1 D1 and its implication in ICAM-1 interaction with LFA-1 and HRV. (A) Ca-traces of
engineered ICAM-1 D1 (magenta) and the wild-type D1 in D1D2 fragment (1IAM in yellow) are drawn with solvent-accessible surface plot (grey). (B)
Hydrogen bond network formed by Thr-2, Thr-23, Ser-67, and Ser-74 at the N-terminal protein core is shown in grey dotted lines with distances in A ˚
from the wild-type ICAM-1 structure (1IAM). Substitutions of T2V, S67A, and T23A in D1 are indicated. (C) A hydrogen bond between Pro-6 and Thr-78
is shown with a dotted line. Substitutions of P63V and T78A found in D1 are indicated. (D) D1 structures of the previous ICAM-1 D1D2 structures
(1IAM in yellow [15], 1IC1 in blue [24], 1MQ8 in green [17]) were superimposed to engineered D1 (3TCX in magenta). The loops, B–C, D–E, and F–G,
are circled with dotted lines. (E) The distances between the Ca atoms (dotted lines in magenta) of the triad Thr-2, Thr-23, and Ser-67, and the Ca
distance between Pro-28 to Thr-23 in previous structures are compared with those in D1 mutant. (F) The superimposed ICAM-1 structures with the
HRV were modeled based on the cryo-EM Ca coordinates of ICAM-1 D1D2 bound to HRV16 (1D3E [31] and 1AYM [45]). (G) The superimposed D1
structures are shown with the aL I domain shown as solvent-accessible surface.
doi:10.1371/journal.pone.0044124.g003
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the a7-helix. Using a comprehensive, systematic approach to
isolate mutations that would enhance protein fold, we have
previously engineered a functional ICAM-1 D1 on its own, fully
active in regard to its interaction with LFA-1 and less active with
HRV [25]. Although as many as seven mutations were necessary
to achieve functional D1 in isolation, our crystal structure revealed
little perturbation in the conformation of the b-strands that form
two faces of the b-sandwich structure. Despite extensive screening
and optimization of crystallization conditions, the engineered
complex in our study had repeatedly produced a large unit cell,
and failed to diffract to high resolution that would greatly aid in
more precise positioning of all the side-chains. However, all 14
complexes in the unit cell were highly superimposable with each
other as well as to the previous crystal structures, validating the
open conformation of the a7-helix of the I domain.
The structural basis of allosteric switching of the integrin I
domains to the conformation that is competent for ligand binding
has been studied extensively. Conformational allostery in the a7-
helix was first evidenced in the aM I domain structure with
glutamic acid of the neighboring I domain coordinating to the
metal ion in the MIDAS [27] and a concomittant downward
displacement of the a7-helix. This was in contrast to later
structures that revealed an upward position of the a7-helix and a
lack of ligation to the MIDAS [34]. The first complex structure of
the I domain with ligands was the a2 I domain bound to a collagen
mimetic peptide, exhibiting a similar downward position for the
a7-helix [28]. However, due to a low affinity of the wild-type LFA-
1 I domain to ligands, previous complex structures with ICAMs
required a pair of cysteines or the mutation (e.g., F292G) that
would directly influence the position of the a7-helix. With the
native sequence in the allosteric site around the a7-helix, the
crystal structure of the complex in this study further underscores
the intrinsic mobility of the a7-helix and how the I domain
allostery is coupled to a global conformation change of integrins.
ICAM-1 consists of five Ig-like domains in its extracellular
region, of which D1 is solely responsible for the molecular contacts
with the LFA-1 I domain and HRV. Despite an extensive set of
mutations in D1, which would convert mainly hydrogen bond
interactions into vdW contacts, the D1 mutant was found to retain
a native conformation of b-strands and b-sandwich fold with a
largest deviation localized to the loops that form the N-terminal
face of the Ig-like fold. Conformational variability of the loops in
D1, analogous to the complementarity determining region (CDR)
in antibodies [35], was also pronounced among the crystal
structures of the wild-type ICAM-1 D1D2 with as much as 1.1,
2.9, and 4.8 A ˚ RMSD between Ca distances in B–C, D–E, and F–
G loops, respectively, whereas the rest of the domain differed by
less than 0.6 A ˚ RMSD. Although the stable D1 mutant retained its
interaction with conformation-specific antibodies and the LFA-1 I
domain, the full-length ICAM-1 D1-D5 containing the mutations
found in D1 displayed lower binding to HRV [25]. In addition to
the proposed role of charge complementarity at the interface
between ICAM-1 and HRV [33,36], the flexible nature of the
loops [15,24] and hydrogen bond network present in the N-
terminal face of ICAM-1 may also be critical to recognition of over
90 different serotypes of rhinovirus by ICAM-1 [37]. The
information gained from the crystal structure of the engineered
ICAM-1 D1 and its comparison with the wild-type structures, i.e.,
the importance of hydrogen bond network in the protein core that
determines the conformation of the CDR-like loops for interaction
with HRV, may provide a further insight into designing a
functional D1 alone that retains full capacity binding to the virus.
Functional D1, due to its low-cost production from bacteria, may
be developed into a decoy antagonist to block LFA-1/ICAM-1
interactions and HRV binding to ICAM-1 expressing host cells.
Materials and Methods
Protein Production and Crystallization Condition
The LFA-1 I domain (Asn-129 - Tyr-307 with a mutation
F265S) and ICAM-1 D1 (Gln-1 - Thr-85 with mutations Q1M,
T2V, I10T, T23A, P38V, P63V, S67A, and T78A) were
expressed in E. coli BL21 (DE3) (Novagen), refolded, and purified
as previously described [25]. Equal molar of the I domain and D1
were mixed in the presence of 1 mM MgCl2 to form the complex,
purified by size exclusion and ion exchange columns, and
concentrated to 11 mg/ml in 50 mM HEPES, pH 7.2, 10%
glycerol. Protein complex was then mixed at equal volume with
the buffer for crystallization (0.1 M HEPES, pH 7.2, 10%
glycerol, 0.4 M Na formate, 0.4 M NaCl, 22% PEG 6000, and
Figure 4. Differences in Ca positions for the superimposed structures of ICAM-1 D1. Pair-wise Ca-Ca distances between wild-type ICAM-1
(1IAM, 1MQ8, and 1IC1) and engineered D1 (3TCX) are plotted. Also, Ca-C a distances among the wild-type ICAM-1 structures are plotted (1IAM to
1MQ8, 1IC1 to 1IAM, and 1MQ8 to 1IC1). Putative interacting residues of ICAM-1 D1 with HRV16 capsid as well as the residues in close contact with
the aL I domain are indicated with brackets and corresponding residue numbers. Arrow bars denote the residues that form the b-strands in ICAM-1
D1.
doi:10.1371/journal.pone.0044124.g004
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Data Collection and Structure Refinement
The diffraction data were collected at Cornell High Energy
Synchrotron Source (CHESS) Beamline F1 and processed with
HKL2000 [38] for integration and scaling. The initial structural
model was obtained by molecular replacement using PHASER
[39] in CCP4 program suite [40]. There were a total of 14
complexes in an asymmetric unit and these complexes were found
one by one [39] using the previous complex structures of ICAMs
and aL I domain (PDB codes 1MQ8 and 3BN3) as search models.
Then the structures were refined with Refmac5 [41]. During
refinement, 28 TLS (Translation/Libration/Screw) groups were
assigned (14 groups for each ICAM (all atoms selected) and 14
groups for each aL I domains (all atoms selected). Considering
relatively low diffraction resolution (3.6 A ˚), tight non-crystallo-
graphic symmetry (NCS) restraints were applied to the 14
complexes. The refined structures were proofread and corrected
with COOT [42] and refined again with Refmac5 until the
crystallographic R and Rfree factors converge to 21.8% and 23.4%,
respectively. The structural refinement using PHENIX [43]
produced essentially the same results with similar R and Rfree
values. The final structures were validated with PDB validation
server (www.pdb.org). The coordinates of our complex structures
have been deposited to the RCSB with the PDB code 3TCX.
Details in data collection and structure refinement can be found in
Table 1.
Structure Alignments and Analysis
Previous structures of the aM (1IDO) [27], a2 (1DZI) [28], and
aL (3F74) [44] I domains were superimposed to the aL I domain of
our structure (3TCX) based on residues in the a6-helix (aM: 278–
288; a2: 294–304; aL: 268–278) (Fig. 1C). Previous complex
structures of aL I domain with ligands, which included ICAM-1
D1D2 (1MQ8) [17], ICAM-3 D1 (1T0P) [20], and ICAM-5
D1D2 (3BN3) [26], were superimposed to the aL I domain of our
structure (3TCX) using residues in the central b-sheet (129–140,
164–181, 231–237). Previous wild-type ICAM-1 D1 structures
(1IAM [15], 1IC1 [24], and 1MQ8) were superimposed to the
ICAM-1 D1 of our structure (3TCX) using the residues in the b-
strands (2–5, 8–11, 15–23, 30–34, 38–42, 50–57, 61–68, and 73–
83). A model structure of ICAM-1 D1 bound to HRV16 was
constructed by aligning HRV16 coat protein (1AYM) [45] and
ICAM-1 structures (residues 1–80) to the corresponding cryo-
electron microscopy (cryo-EM) Ca coordinates of ICAM-1 D1D2
bound to HRV (1D3E) [31] (Fig. 3F). All the molecular graphic
figures were made using PyMOL (DeLano, W.L.).
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